Gain Therapeutics Plans Public Offering to Fund Neurodegenerative Treatment Development

Gain Therapeutics (GANX) has announced plans for an underwritten public offering of common stock and warrants to raise funds for the continued clinical and nonclinical development of its lead product candidate, GT-02287, aimed at treating neurodegenerative diseases including GBA1 Parkinson's disease. The offering's size, terms, and completion depend on market conditions, with Newbridge Securities Corporation acting as sole book-running manager. Following the announcement, Gain Therapeutics' stock price dropped notably, reflecting market reaction. Analyst consensus projects a significant one-year price target average of $8.00, suggesting a substantial upside potential compared to the current trading price around $1.70, and brokerage firms rate the stock as an 'Outperform.' The company also plans to grant underwriters an option to purchase additional shares and warrants, and the offering will be conducted under an existing SEC shelf registration. The proceeds are intended to support both the development of GT-02287 and general corporate purposes.